Efficacy News and Research

RSS
AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO third quarter total collaboration revenues increase to $6.2 million

Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

Patient share of Actemra for RA to exceed patient share for Cimzia and Simponi, says Report

Patient share of Actemra for RA to exceed patient share for Cimzia and Simponi, says Report

Nanotherapeutics receives contract from DOD to support clinical trial for treating dehisced surgical wounds

Nanotherapeutics receives contract from DOD to support clinical trial for treating dehisced surgical wounds

Phase III study suggests CYCLOSET tablets improve glycemic control

Phase III study suggests CYCLOSET tablets improve glycemic control

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction

Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction

PolyMedix receives $488,958 grants under QTDP program

PolyMedix receives $488,958 grants under QTDP program

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Bortezomib reduces inflammation and promotes bone healing in arthritis models

Bortezomib reduces inflammation and promotes bone healing in arthritis models

QLT third quarter sales decreases 12.9% to $20.5 million

QLT third quarter sales decreases 12.9% to $20.5 million

TSO3 third quarter revenue decreases from $126,162 to $122,759

TSO3 third quarter revenue decreases from $126,162 to $122,759

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Systagenix introduces world's first rapid point of test in wound care

Systagenix introduces world's first rapid point of test in wound care

EUREKA program confirms ability of HIFU technology to deliver cancer drugs

EUREKA program confirms ability of HIFU technology to deliver cancer drugs

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.